

# SAFETY DATA SHEET



## Lynestrenol Formulation



Version 5.2      Revision Date: 06.04.2024      SDS Number: 449559-00017      Date of last issue: 30.09.2023  
Date of first issue: 15.01.2016

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Lynestrenol Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Germ cell mutagenicity, Category 1B	H340: May cause genetic defects.
Carcinogenicity, Category 2	H351: Suspected of causing cancer.
Reproductive toxicity, Category 1A	H360Fd: May damage fertility. Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H340 May cause genetic defects.  
H351 Suspected of causing cancer.

# SAFETY DATA SHEET



## Lynestrenol Formulation



Version 5.2      Revision Date: 06.04.2024      SDS Number: 449559-00017      Date of last issue: 30.09.2023  
Date of first issue: 15.01.2016

H360Fd      May damage fertility. Suspected of damaging the unborn child.  
H373      May cause damage to organs through prolonged or repeated exposure.

Precautionary statements :

### Prevention:

P201      Obtain special instructions before use.  
P260      Do not breathe dust.  
P280      Wear protective gloves/ protective clothing/ eye protection/ face protection.

### Response:

P308 + P313      IF exposed or concerned: Get medical advice/ attention.

### Storage:

P405      Store locked up.

Hazardous components which must be listed on the label:

Lynestrenol

### Additional Labelling

EUH208      Contains Tocopherol. May produce an allergic reaction.

## 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Lynestrenol	52-76-6 200-151-4	Acute Tox. 4; H302 Muta. 1B; H340 Carc. 2; H351 Repr. 1A; H360Fd STOT RE 1; H372 (Blood, Mammary gland, Uterus (including cervix), Ovary)	>= 1 - < 10
Tocopherol	10191-41-0 233-466-0	Skin Sens. 1B; H317	>= 0,1 - < 1

## Lynestrenol Formulation

Version 5.2      Revision Date: 06.04.2024      SDS Number: 449559-00017      Date of last issue: 30.09.2023  
Date of first issue: 15.01.2016

---

For explanation of abbreviations see section 16.

---

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : May cause genetic defects.  
Suspected of causing cancer.  
May damage fertility. Suspected of damaging the unborn child.  
May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.
- May produce an allergic reaction.

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

## Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	06.04.2024	449559-00017	Date of first issue: 15.01.2016

---

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

#### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).

## Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	06.04.2024	449559-00017	Date of first issue: 15.01.2016

---

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**6.4 Reference to other sections**

See sections: 7, 8, 11, 12 and 13.

---

**SECTION 7: Handling and storage****7.1 Precautions for safe handling**

- |                         |   |  |
|-------------------------|---|--|
| Technical measures      | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.   |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.  |
| Advice on safe handling | : | Do not get on skin or clothing.<br>Do not breathe dust.<br>Do not swallow.<br>Avoid contact with eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.   |

**7.2 Conditions for safe storage, including any incompatibilities**

- |   |   |   |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
| Advice on common storage                      | : | Do not store with the following product types:  |

# SAFETY DATA SHEET



## Lynestrenol Formulation



Version 5.2      Revision Date: 06.04.2024      SDS Number: 449559-00017      Date of last issue: 30.09.2023  
Date of first issue: 15.01.2016

Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Starch	9005-25-8	OEL-RL	10 mg/m <sup>3</sup>	ZA OEL
Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents				
Lynestrenol	52-76-6	TWA	1 µg/m <sup>3</sup> (OEB 4)	Internal
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal
Talc	14807-96-6	OEL-RL (respirable dust fraction)	4 mg/m <sup>3</sup>	ZA OEL
Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents				

#### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerine	Workers	Inhalation	Long-term local effects	56 mg/m <sup>3</sup>
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local effects	33 mg/m <sup>3</sup>
Tocopherol	Workers	Inhalation		44 mg/m <sup>3</sup>
	Workers	Skin contact		125 mg/kg bw/day
	Consumers	Inhalation		10,8 mg/m <sup>3</sup>
	Consumers	Skin contact		62,5 mg/kg bw/day
	Consumers	Ingestion		6,25 mg/kg bw/day

#### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Glycerine	Fresh water	0,885 mg/l
	Marine water	0,0885 mg/l
	Intermittent use/release	8,85 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3,3 mg/kg dry

## Lynestrenol Formulation

Version 5.2      Revision Date: 06.04.2024      SDS Number: 449559-00017      Date of last issue: 30.09.2023  
 Date of first issue: 15.01.2016

		weight (d.w.)
	Marine sediment	0,33 mg/kg dry weight (d.w.)
	Soil	0,141 mg/kg dry weight (d.w.)

**8.2 Exposure controls****Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

**Personal protective equipment**

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type (A-P)

**SECTION 9: Physical and chemical properties****9.1 Information on basic physical and chemical properties**

Appearance	:	powder
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available

# SAFETY DATA SHEET



## Lynestrenol Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	06.04.2024	449559-00017	Date of first issue: 15.01.2016

---

Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Flammability (liquids)	:	No data available
Particle size	:	No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means.
---------------------	---	---



# SAFETY DATA SHEET



## Lynestrenol Formulation



Version 5.2      Revision Date: 06.04.2024      SDS Number: 449559-00017      Date of last issue: 30.09.2023  
Date of first issue: 15.01.2016

---

Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

#### Components:

##### Lynestrenol:

Acute oral toxicity : LD50: > 1.000 - 8.000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Mouse): 110 mg/kg  
Application Route: Intraperitoneal

##### Tocopherol:

Acute oral toxicity : LD50 (Rat): > 4.000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 3.000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Tocopherol:

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

## Lynestrenol Formulation

Version 5.2      Revision Date: 06.04.2024      SDS Number: 449559-00017      Date of last issue: 30.09.2023  
Date of first issue: 15.01.2016

---

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### **Tocopherol:**

Species : Rabbit  
Method : OECD Test Guideline 405  
Result : No eye irritation

### Respiratory or skin sensitisation

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

#### Components:

##### **Tocopherol:**

Test Type : Local lymph node assay (LLNA)  
Exposure routes : Skin contact  
Species : Mouse  
Method : OECD Test Guideline 429  
Result : positive

Assessment : Probability or evidence of low to moderate skin sensitisation rate in humans

### Germ cell mutagenicity

May cause genetic defects.

#### Components:

##### **Lynestrenol:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Result: positive

Test Type: sister chromatid exchange assay  
Result: positive

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: positive

Test Type: sister chromatid exchange assay  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: positive

Test Type: dominant lethal test  
Species: Mouse

# SAFETY DATA SHEET



## Lynestrenol Formulation



Version 5.2      Revision Date: 06.04.2024      SDS Number: 449559-00017      Date of last issue: 30.09.2023  
Date of first issue: 15.01.2016

---

Application Route: Intraperitoneal  
Result: positive

Germ cell mutagenicity- Assessment : Positive result(s) from in vivo somatic cell mutagenicity tests in mammals. Evidence that the substance has potential to cause mutations to germ cells

### **Tocopherol:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### **Carcinogenicity**

Suspected of causing cancer.

### **Components:**

#### **Lynestrenol:**

Species : Mouse  
Application Route : Oral  
Exposure time : 80 weeks  
Result : positive  
Tumor Type : breast tumors, Liver  
Remarks : Benign and malignant tumor(s)

Species : Rat  
Application Route : Oral  
Exposure time : 80 weeks  
Result : positive  
Tumor Type : breast tumors

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in animal studies

#### **Tocopherol:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 104 weeks  
Result : negative  
Remarks : Based on data from similar materials

### **Reproductive toxicity**

May damage fertility. Suspected of damaging the unborn child.

## Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	06.04.2024	449559-00017	Date of first issue: 15.01.2016

---

**Components:****Lynestrenol:**

- Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, males  
Application Route: Oral  
Fertility: LOAEL: 20 mg/kg body weight  
Remarks: Impaired spermatogenesis
- Test Type: Fertility/early embryonic development  
Species: Rat, females  
Application Route: Oral  
Fertility: LOAEL: 375 µg/kg  
Result: Maternal toxicity observed., Effects on fertility
- Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Oral  
Fertility: LOAEL: 1.300 µg/kg  
Result: Effects on fertility, Postimplantation loss.
- Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 0,1 mg/kg body weight  
Result: Effects on foetal development
- Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 0,1 mg/kg body weight  
Result: Effects on foetal development, Postimplantation loss.
- Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments., Positive evidence of adverse effects on sexual function and fertility from human epidemiological studies.

**Tocopherol:**

- Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

## Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	06.04.2024	449559-00017	Date of first issue: 15.01.2016

---

**Components:****Lynestrenol:**

Target Organs	:	Blood, Mammary gland, Uterus (including cervix), Ovary
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Tocopherol:**

Species	:	Rat
NOAEL	:	500 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Lynestrenol:**

Ingestion	:	Target Organs: Uterus (including cervix) Target Organs: breasts Target Organs: ovaries Target Organs: Blood Symptoms: Headache, Nausea, Abdominal pain, Rash, Dizziness, Tremors, Sweating, Vomiting, migraine, acne, breast tenderness, gynecomastia, menstrual irregularities, ovarian cysts Remarks: Used to prevent pregnancy
-----------	---	--

---

**SECTION 12: Ecological information****12.1 Toxicity****Components:****Tocopherol:**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
------------------	---	---

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 23,53 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
---	---	--

Toxicity to algae/aquatic	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 25,8
---------------------------	---	--

## Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	06.04.2024	449559-00017	Date of first issue: 15.01.2016

---

plants		mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		EC50 (Pseudokirchneriella subcapitata (green algae)): > 25,8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	:	EC50 : > 937 mg/l Exposure time: 30 min Method: ISO 8192 Remarks: Based on data from similar materials
Toxicity to fish (Chronic toxicity)	:	NOEC: > 100 mg/l Exposure time: 28 d Species: Oncorhynchus mykiss (rainbow trout) Remarks: Based on data from similar materials

**12.2 Persistence and degradability****Components:****Tocopherol:**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 20 % Exposure time: 28 d Method: OECD Test Guideline 301F
------------------	---	---

**12.3 Bioaccumulative potential**

No data available

**12.4 Mobility in soil**

No data available

**12.5 Results of PBT and vPvB assessment****Product:**

Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	---	--

**12.6 Other adverse effects****Product:**

Endocrine disrupting potential	:	The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
--------------------------------	---	---

## Lynestrenol Formulation

Version 5.2      Revision Date: 06.04.2024      SDS Number: 449559-00017      Date of last issue: 30.09.2023  
Date of first issue: 15.01.2016

---

**SECTION 13: Disposal considerations****13.1 Waste treatment methods**

- Product : Dispose of in accordance with local regulations.  
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.  
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.  
Do not dispose of waste into sewer.
- Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.
- 

**SECTION 14: Transport information****14.1 UN number**

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

**14.2 UN proper shipping name**

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

**14.3 Transport hazard class(es)**

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

**14.4 Packing group**

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA (Cargo) : Not regulated as a dangerous good  
IATA (Passenger) : Not regulated as a dangerous good

## Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	06.04.2024	449559-00017	Date of first issue: 15.01.2016

---

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H302	:	Harmful if swallowed.
H317	:	May cause an allergic skin reaction.
H340	:	May cause genetic defects.
H351	:	Suspected of causing cancer.
H360Fd	:	May damage fertility. Suspected of damaging the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure.

### Full text of other abbreviations

Acute Tox.	:	Acute toxicity
Carc.	:	Carcinogenicity
Muta.	:	Germ cell mutagenicity
Repr.	:	Reproductive toxicity
Skin Sens.	:	Skin sensitisation
STOT RE	:	Specific target organ toxicity - repeated exposure
ZA OEL	:	South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits
ZA OEL / OEL-RL	:	Occupational Exposure Limit Restricted limit - 8- hour exposure or equivalent (12 hour shifts)



## Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	06.04.2024	449559-00017	Date of first issue: 15.01.2016

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

Muta. 1B	H340
Carc. 2	H351
Repr. 1A	H360Fd
STOT RE 2	H373

**Classification procedure:**

Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

# SAFETY DATA SHEET



## Lynestrenol Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	06.04.2024	449559-00017	Date of first issue: 15.01.2016

---

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN